IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11319299 B1

PDFFull Text
Date of Patent:
May. 03, 2022

Filed:

Mar. 01, 2017

Substituted carboxamides as inhibitors of wdr5 protein-protein binding

Applicant:

Propellon Therapeutics Inc., Toronto, CA;

Inventors:

Rima Al-Awar, Toronto, CA;

Carlos Armando Zepeda-Velazquez, Mississauga, CA;

Gennady Poda, Toronto, CA;

Methvin Isaac, Brampton, CA;

David Uehling, Toronto, CA;

Brian Wilson, Mississauga, CA;

Babu Joseph, Oakville, CA;

Yong Liu, Oakville, CA;

Pandiaraju Subramanian, Oakville, CA;

Ahmed Mamai, Mississauga, CA;

Michael Prakesch, Toronto, CA;

Julia Kathleen Stille, Ottawa, CA;

Assignee:

Propellon Therapeutics Inc., Toronto, CA;

Attorneys:

Cooley LLP

J. Dean Farmer

Serge R. Banini

Primary Examiner:

Douglas M Willis

Int. Cl.
CPC ...
A61K 31/167 (2006.01); C07C 233/15 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 403/10 (2006.01); C07D 401/10 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01); A61K 45/06 (2006.01); A61P 35/02 (2006.01);
U.S. Cl.
CPC ...
C07D 401/12 (2013.01); A61K 45/06 (2013.01); C07D 401/10 (2013.01); C07D 401/14 (2013.01); C07D 403/10 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); A61P 35/02 (2018.01);
Abstract

The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

Find Patent Forward Citations

Loading…